These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30826914)

  • 1. Is Early Reimplantation of the Duodenal-Jejunal Bypass Liner Viable?
    Leventi E; Günthert SJ; Stier C; Staikov P; Stein J; Farrag K
    Obes Surg; 2019 May; 29(5):1690-1693. PubMed ID: 30826914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is reimplantation of the duodenal-jejunal bypass liner feasible?
    Koehestanie P; Betzel B; Aarts EO; Janssen IM; Wahab P; Berends FJ
    Surg Obes Relat Dis; 2015; 11(5):1099-104. PubMed ID: 25979208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in BMI, Glycemic Control and Obesity-Associated Comorbidities After Explantation of the Duodenal-Jejunal Bypass Liner (DJBL).
    Riedel N; Laubner K; Lautenbach A; Schön G; Schlensak M; Stengel R; Eberl T; Dederichs F; Aberle J; Seufert J
    Obes Surg; 2018 Aug; 28(8):2187-2196. PubMed ID: 29504053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical follow-up on weight loss, glycemic control, and safety aspects of 24 months of duodenal-jejunal bypass liner implantation.
    Betzel B; Cooiman MI; Aarts EO; Janssen IMC; Wahab PJ; Groenen MJM; Drenth JPH; Berends FJ
    Surg Endosc; 2020 Jan; 34(1):209-215. PubMed ID: 30877567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial.
    Koehestanie P; de Jonge C; Berends FJ; Janssen IM; Bouvy ND; Greve JW
    Ann Surg; 2014 Dec; 260(6):984-92. PubMed ID: 25072436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weight reduction and improvement in diabetes by the duodenal-jejunal bypass liner: a 198 patient cohort study.
    Betzel B; Homan J; Aarts EO; Janssen IMC; de Boer H; Wahab PJ; Groenen MJM; Berends FJ
    Surg Endosc; 2017 Jul; 31(7):2881-2891. PubMed ID: 27804045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal evaluation of efficacy, safety and nutritional status during one-year treatment with the duodenal-jejunal bypass liner.
    Riedel N; Laubner K; Lautenbach A; Schön G; Schlensak M; Stengel R; Eberl T; Dederichs F; Aberle J; Seufert J
    Surg Obes Relat Dis; 2018 Jun; 14(6):769-779. PubMed ID: 29650340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of proximal small bowel exclusion by duodenal-jejunal bypass liner on weight reduction and glycemic control in diabetic patients.
    Deutsch L; Ben Haim L; Sofer Y; Gluck N; Santo E; Fishman S
    Surg Obes Relat Dis; 2018 Oct; 14(10):1561-1569. PubMed ID: 30449512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in glycemic control and body weight after explantation of the duodenal-jejunal bypass liner.
    Betzel B; Koehestanie P; Homan J; Aarts EO; Janssen IM; de Boer H; Wahab PJ; Groenen MJ; Berends FJ
    Gastrointest Endosc; 2017 Feb; 85(2):409-415. PubMed ID: 27451295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety experience with the duodenal-jejunal bypass liner: an endoscopic treatment for diabetes and obesity.
    Betzel B; Koehestanie P; Aarts EO; Dogan K; Homan J; Janssen IM; Wahab PJ; Groenen MJ; Berends FJ
    Gastrointest Endosc; 2015 Nov; 82(5):845-52. PubMed ID: 25952090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline glycated hemoglobin levels are associated with duodenal-jejunal bypass liner-induced weight loss in obese patients.
    Muñoz R; Dominguez A; Muñoz F; Muñoz C; Slako M; Turiel D; Pimentel F; Sharp A; Escalona A
    Surg Endosc; 2014 Apr; 28(4):1056-62. PubMed ID: 24196558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of glucometric 'dynamical' variables on duodenal-jejunal bypass liner (DJBL) anthropometric and metabolic outcomes.
    Colás A; Varela M; Mraz M; Novak D; Cuesta-Frau D; Vigil L; Benes M; Pelikanova T; Haluzik M; Burda V; Vargas B
    Diabetes Metab Res Rev; 2020 May; 36(4):e3287. PubMed ID: 31916665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine effects of duodenal-jejunal exclusion in obese patients with type 2 diabetes mellitus.
    Kaválková P; Mráz M; Trachta P; Kloučková J; Cinkajzlová A; Lacinová Z; Haluzíková D; Beneš M; Vlasáková Z; Burda V; Novák D; Petr T; Vítek L; Pelikánová T; Haluzík M
    J Endocrinol; 2016 Oct; 231(1):11-22. PubMed ID: 27474690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of 6 and 12 months Duodenal-Jejunal Bypass Liner Treatment on Obesity and Type 2 Diabetes: a Crossover Cohort Study.
    van Rijn S; Betzel B; de Jonge C; van Dijk DPJ; Janssen IM; Berends FJ; Bouvy ND; Greve JWM
    Obes Surg; 2018 May; 28(5):1255-1262. PubMed ID: 29110244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight loss and metabolic improvement in morbidly obese subjects implanted for 1 year with an endoscopic duodenal-jejunal bypass liner.
    Escalona A; Pimentel F; Sharp A; Becerra P; Slako M; Turiel D; Muñoz R; Bambs C; Guzmán S; Ibáñez L; Gersin K
    Ann Surg; 2012 Jun; 255(6):1080-5. PubMed ID: 22534421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes.
    de Jonge C; Rensen SS; Verdam FJ; Vincent RP; Bloom SR; Buurman WA; le Roux CW; Schaper NC; Bouvy ND; Greve JW
    Obes Surg; 2013 Sep; 23(9):1354-60. PubMed ID: 23526068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of the Duodeno-Jejunal Bypass Liner in Patients With Metabolic Syndrome: A Multicenter Randomized Controlled Trial (ENDOMETAB).
    Caiazzo R; Branche J; Raverdy V; Czernichow S; Carette C; Robert M; Disse E; Barthet M; Cariou B; Msika S; Behal H; Denies F; Dervaux B; Duhamel A; Verkindt H; Pattou F
    Ann Surg; 2020 Nov; 272(5):696-702. PubMed ID: 32889869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus: A case control study.
    Laubner K; Riedel N; Fink K; Holl RW; Welp R; Kempe HP; Lautenbach A; Schlensak M; Stengel R; Eberl T; Dederichs F; Schwacha H; Seufert J; Aberle J
    Diabetes Obes Metab; 2018 Aug; 20(8):1868-1877. PubMed ID: 29569313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner.
    de Moura EG; Martins BC; Lopes GS; Orso IR; de Oliveira SL; Galvão Neto MP; Santo MA; Sakai P; Ramos AC; Garrido Júnior AB; Mancini MC; Halpern A; Cecconello I
    Diabetes Technol Ther; 2012 Feb; 14(2):183-9. PubMed ID: 21932999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute pancreatitis as an adverse event in patients with the duodenal-jejunal bypass liner.
    Betzel B; Homan J; Aarts E; Janssen I; Spanier M; Wahab P; Groenen M; Berends F
    Endoscopy; 2015 Nov; 47(11):1050-3. PubMed ID: 26021308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.